TREM1/Dap12-based CAR-T cells show potent antitumor activity

Written by Chen B, Zhou M, Zhang H et al.

CAR-T treatment gains huge success in blood cancer immunotherapy. However, clinic benefits from CD3ζ-based CAR-T transfer cannot be reliably repeated in solid tumors. A recent research article published in Immunotherapy has highlighted the antitumor activity of TREM1/Dap12-based CAR-T cells have both in vitro and in vivo. Abstract Aim: Chimeric antigen receptor-engineered T (CAR-T) cells have gained huge success in treating hematological malignancies, yet the CD3ζ-based CAR-T therapies have not shown comparable clinical benefits in solid tumors. We designed an alternative chimeric immunoreceptor in which a single-chain variable fragment was fused to the transmembrane-cytoplasmic domains of triggering receptor expressed on myeloid (TREM1), which may show...

To view this content, please register now for access

It's completely free